Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review

We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers. The patient received three cycles of an “alectinib + Vincristine +...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongxia Wang, Junjun Bai, Bei Zhang, Zhixin Pei, Yingxin Zhao, Jingjing Gu, Zhiyu Fang, Miaomiao Liu, Xun Liang, Qinglin Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
ALK+ LBCL
alectinib
bortezomib
lenalidomide
BV monoclonal antibody
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1480880/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items